{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:56:28Z","timestamp":1793048188371,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important role of this cytokine in immune biology, and the ability to engineer variant proteins with potentially improved antitumor immunomodulatory activity and reduced toxicity. Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development.<\/jats:p>","DOI":"10.1136\/jitc-2022-006346","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T10:40:13Z","timestamp":1673001613000},"page":"e006346","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"first","affiliation":[{"name":"Yale Cancer Center, Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Synthekine, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"2025100311465674000_11.1.e006346.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845"},{"key":"2025100311465674000_11.1.e006346.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"2025100311465674000_11.1.e006346.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"2025100311465674000_11.1.e006346.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y"},{"key":"2025100311465674000_11.1.e006346.5","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80067-O"},{"key":"2025100311465674000_11.1.e006346.6","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603272"},{"key":"2025100311465674000_11.1.e006346.7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67008"},{"key":"2025100311465674000_11.1.e006346.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1631"},{"key":"2025100311465674000_11.1.e006346.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431"},{"key":"2025100311465674000_11.1.e006346.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"key":"2025100311465674000_11.1.e006346.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002569107"},{"key":"2025100311465674000_11.1.e006346.12","doi-asserted-by":"crossref","first-page":"S901","DOI":"10.1016\/j.annonc.2022.07.911","article-title":"785O pivot io 001: first disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)","volume":"33","author":"Diab","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025100311465674000_11.1.e006346.13","doi-asserted-by":"crossref","first-page":"S1433","DOI":"10.1016\/j.annonc.2022.08.073","article-title":"LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator\u2019s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)","volume":"33","author":"Tannir","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025100311465674000_11.1.e006346.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3"},{"key":"2025100311465674000_11.1.e006346.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"2025100311465674000_11.1.e006346.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1510"},{"key":"2025100311465674000_11.1.e006346.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7661"},{"key":"2025100311465674000_11.1.e006346.18","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.4049\/jimmunol.162.8.4943","article-title":"A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells","volume":"162","author":"Carson","year":"1999","journal-title":"J Immunol"},{"key":"2025100311465674000_11.1.e006346.19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.169.1.161"},{"key":"2025100311465674000_11.1.e006346.20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"2025100311465674000_11.1.e006346.21","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1158\/1538-7445.AM2022-3518","article-title":"Abstract 3518: AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy","volume":"82","author":"Moynihan","year":"2022","journal-title":"Cancer Res"},{"key":"2025100311465674000_11.1.e006346.22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"2025100311465674000_11.1.e006346.23","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1744"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:47:04Z","timestamp":1759517224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,6]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-006346"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006346","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}